TIETOJA TÄSTÄ PODCASTISTA 🔗

Päivitä taajuus:
biweekly
Keskimääräinen äänen pituus:
41 minutes
Vierashaastattelut
On sponsoreita
Englanti
Yhdysvallat
18 jaksoa
vuodesta 26. tammikuuta 2026
episodic

VIIMEISIN JAKSO 🔗

In this episode, Brendan McGrath shares his story of him being the first employee of WuXi Biologics in Ireland and how he helped turn an empty site into a 46,000 m² biologics facility in Dundalk. He shares the greenfield risk he took, building through COVID and Brexit with 1,800 workers on site, a…

HAE EDELLISIÄ EPISODEJA

Hae kanavan Pharma Conversations Podcast vanhoja jaksoja.

EDELLISET JAKSOT

Executive Director of the ARC Hub* for Therapeutics, Araz Raoof, joins Pharma Conversations to unpack why Europe leads the world in scientific papers yet lags in new drug approvals, and how Ireland’s ARC Hub for Therapeutics is trying to change that. She explains the “valley of death” where acade…
In this episode of Pharma Conversations, Paul McCabe, COO of APC/VLE unpacks the hidden world of Ireland’s indigenous biopharma SMEs, and why, despite a world-class multinational presence, the ecosystem is incomplete. He explores funding gaps, missing infrastructure, talent and entrepreneurial ba…
Sustainability in pharma isn’t a side project anymore – it’s fast becoming core operational excellence. In this episode of Pharma Conversations, we sit down with Michael Kilkelly (IBEC) to explore how Irish pharma is leading on decarbonisation, the real challenges behind scope 1–3 emissions, and pr…
In this episode John Shabushnig, founder of Insight Pharma Consulting explains what visual inspection really means for injectable products, from manual methods to advanced automated systems. He tackles difficult-to-inspect products, visible particle risk, and common pitfalls in validating automati…
In this episode of Pharma Conversations, Maria Ginnelly explains the impact of the EU GMP Annex 1 (section 5.5) on the sterilisation of indirect product-contact parts in sterile manufacturing. She explains why regulators now expect these parts to be treated as critical, why VHP alone is insufficien…
In this episode, Charlie Maxwell of Orion GXP Consulting, breaks down what non‑EU pharma and biotech companies need to get right when launching in Europe, from choosing the right HQ location and operating model to deciding between building infrastructure and outsourcing to CDMOs, 3PLs and contract …
In this episode, Martin Lush of Martin Lush Consulting, breaks down how pharma organizations can safely and effectively adopt AI without sacrificing GMP, quality, or critical thinking. He explains the four types of AI mindsets in pharma, why “AI knows nothing,” and how overreliance and poor foundat…
In this episode Craig Jacobs, Quality Culture Momentum Specialist of Affirm8 Quality Consultancy, unpacks what “quality culture” truly means in life sciences organizations. He explains that real quality shows up when no one is watching on the night shift, in audits, and in everyday process executio…
In this episode, tech transfer expert and lecturer Joe Brady explains why most projects are “already late on day one” and unpacks the real causes of delay across the product lifecycle, from stability studies and PPQ batches to warehouses, materials, and analytical methods. He contrasts innovator to…
Vastuuvapautusilmoitus: Tälle sivulle upotettu podcast ja kuvitus ovat peräisin Pharma Conversations Podcast:ltä, joka on sen omistajan omaisuutta, eikä se ole sidoksissa Listen Notes, Inc:n tukemaan.